Difference between revisions of "User:Shawndouglas/sandbox/sublevel35"
From LIMSWiki
< User:Shawndouglas | sandbox
Jump to navigationJump to searchShawndouglas (talk | contribs) |
Shawndouglas (talk | contribs) |
||
| Line 121: | Line 121: | ||
* {{cite journal |title=Safety considerations in the laboratory testing of specimens suspected or known to contain the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |journal=American Journal of Clinical Pathology |author=Iwen, P.C.; Stiles, K.L.; Pantella, M.A. |at=aqaa047 |year=2020 |doi=10.1093/ajcp/aqaa047 |pmid=32190890}} | * {{cite journal |title=Safety considerations in the laboratory testing of specimens suspected or known to contain the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |journal=American Journal of Clinical Pathology |author=Iwen, P.C.; Stiles, K.L.; Pantella, M.A. |at=aqaa047 |year=2020 |doi=10.1093/ajcp/aqaa047 |pmid=32190890}} | ||
* {{cite journal |title=Laboratory diagnosis of emerging human coronavirus infections – The state of the art |journal=Emerging Microbes & Infections |author=Loeffelholz, M.J.; Tang, T.-W. |volume=9 |issue=1 |pages=747–56 |year=2020 |doi=10.1080/22221751.2020.1745095 |pmid=32196430}} | |||
===4.5 Public health lab directory=== | ===4.5 Public health lab directory=== | ||
Revision as of 18:47, 3 April 2020
4. Final thoughts and additional resources
4.1 Final thoughts
4.2 Key guidance documents
- Centers for Disease Control and Prevention (24 March 2020). "Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html.
- Centers for Disease Control and Prevention (24 March 2020). "Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html.
- Centers for Disease Control and Prevention (31 March 2020). "Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html.
- Occupational Safety and Health Administration (March 2020). "Guidance on Preparing Workplaces for COVID-19" (PDF). OSHA 3990-03 2020. Occupational Safety and Health Administration. https://www.osha.gov/Publications/OSHA3990.pdf.
- Public Health England (28 March 2020). "COVID-19: Guidance for sampling and for diagnostic laboratories". U.K Government. https://www.gov.uk/government/publications/wuhan-novel-coronavirus-guidance-for-clinical-diagnostic-laboratories.
- Public Health Laboratory Network (1 April 2020). "PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19)". Department of Health, Australian Government. https://www.health.gov.au/resources/publications/phln-guidance-on-laboratory-testing-for-sars-cov-2-the-virus-that-causes-covid-19.
- U.S. Food and Drug Administration (25 March 2020). "Enforcement Policy for Face Masks and Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency". FDA-2020-D-1138-0013. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-face-masks-and-respirators-during-coronavirus-disease-covid-19-public-health.
- U.S. Food and Drug Administration (30 March 2020). "Enforcement Policy for Gowns, Other Apparel, and Gloves During the Coronavirus Disease (COVID-19) Public Health Emergency". FDA-2020-D-1138-0023. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-gowns-other-apparel-and-gloves-during-coronavirus-disease-covid-19-public-health.
- U.S. Food and Drug Administration (16 March 2020). "Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency". FDA-2020-D-0987-0012. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-diagnostic-tests-coronavirus-disease-2019-during-public-health-emergency.
- World Health Organization, et al. (19 March 2020). "Laboratory biosafety guidance related to coronavirus disease (COVID-19): Interim guidance, 19 March 2020". WHO/WPE/GIH/2020.2. World Health Organization. https://apps.who.int/iris/handle/10665/331500.
- World Health Organization, et al. (19 March 2020). "Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: Interim guidance, 19 March 2020". WHO/COVID-19/laboratory/2020.5. World Health Organization. https://apps.who.int/iris/handle/10665/331501.
4.3 Web portals
4.3.1 U.S. agency portals
- Coronavirus Disease 2019 (COVID-19) - Information for Healthcare Professionals (CDC)
- Coronavirus Disease 2019 (COVID-19) - Information for Laboratories (CDC)
- COVID-19-Related Guidance Documents for Industry, FDA Staff, and Other Stakeholders (FDA)
- Coronavirus (COVID-19) Response (FEMA)
4.3.2 U.S. state and territory portals
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
U.S. territories
4.3.3 Other national and multinational portals
World Health Organization (WHO) and regionals
- WHO
- WHO Africa
- WHO Americas
- WHO Eastern Mediterranean
- WHO Europe
- WHO South-East Asia
- WHO Western Pacific
4.4 Key journal articles
- Iwen, P.C.; Stiles, K.L.; Pantella, M.A. (2020). "Safety considerations in the laboratory testing of specimens suspected or known to contain the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)". American Journal of Clinical Pathology: aqaa047. doi:10.1093/ajcp/aqaa047. PMID 32190890.
- Loeffelholz, M.J.; Tang, T.-W. (2020). "Laboratory diagnosis of emerging human coronavirus infections – The state of the art". Emerging Microbes & Infections 9 (1): 747–56. doi:10.1080/22221751.2020.1745095. PMID 32196430.
